Silence Therapeutics (SLN) Cash & Equivalents (2018 - 2026)

Silence Therapeutics has reported Cash & Equivalents for 9 years, with the latest figure at $70.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 48.64% year-over-year to $70.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.1 million (down 48.64% YoY) and the FY2025 annual result came in at $11.3 million, down 90.71% from the prior year.
• Cash & Equivalents advanced to $70.1 million in Q1 2026 per SLN's latest filing, from $11.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $136.5 million in Q1 2025 and troughed at $11.3 million in Q4 2025.
• A 5-year average of $76.8 million and a median of $68.6 million in 2026 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 80.93% in 2024, then sank 90.71% in 2025.
• Over 5 years, Cash & Equivalents stood at $64.3 million in 2022, then advanced by 4.3% to $67.1 million in 2023, then soared by 80.93% to $121.3 million in 2024, then tumbled by 90.71% to $11.3 million in 2025, then surged by 521.62% to $70.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $70.1 million, $11.3 million, and $102.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.